Results
We identified 705,924 reports, of which 702,072 were applicable excluding non-oral bisphosphonate users and concomitant use of other osteoporosis drugs. As shown in Table 1, disproportionality for cardiac events was observed in romosozumab users (ROR: 11.5, 95% CI: 8.58–15.2; P < 0.01) and teriparatide users (ROR: 1.82, 95% CI: 1.22–2.63; P < 0.01). Disproportionality for cerebrovascular events was observed in only romosozumab users (ROR: 7.03, 95% CI: 5.46–8.93; P < 0.01).
Table 2 shows that the risk of cardiac events was significantly increased in the presence of cardiac disease (OR: 2.74, 95% CI: 1.37–5.49; P < 0.01), hypertension (OR: 1.97, 95% CI: 1.07–3.63; P = 0.03), and diabetes (OR: 2.36, 95% CI: 1.16–4.80; P = 0.02). The risk of cerebrovascular events was significantly increased in the presence of cerebrovascular disease (OR: 4.76, 95% CI: 1.97–11.5; P < 0.01), and hypertension (OR: 2.53, 95% CI: 1.49–4.31; P < 0.01).